Fibromodulin Modulation for Myofibroblast Activity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are ineffective in treating or ameliorating conditions associated with excessive or deficient myofibroblast activities, which are linked to various diseases and biological processes.
Innovation Solution
Modulating myofibroblast activity by adjusting fibromodulin levels in a subject, either by increasing or decreasing fibromodulin, using fibromodulin protein or peptides, and employing agents like TGF-β1 to promote differentiation and apoptosis, or using anti-sense oligonucleotides and antibodies to inhibit fibromodulin activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods are used, then existing therapeutic approaches are applied, but they are ineffective in treating conditions associated with excessive or deficient myofibroblast activities
Solution Approach 1:
The patent changes the molecular parameter by modulating fibromodulin levels (increasing or decreasing) to achieve therapeutic effects. This parameter change approach allows the same mechanism to address multiple disorders with excessive or deficient myofibroblast activity, including skin fibrosis, organ fibrosis, and vascular diseases, thereby improving both treatment effectiveness and versatility simultaneously
2Duration of action of moving object
If fibromodulin level is increased to promote myofibroblast differentiation and apoptosis, then early but short duration myofibroblast activity is enhanced, but prolonged myofibroblast activity cannot be addressed
Solution Approach 1:
The patent employs dynamic modulation of fibromodulin levels rather than static treatment. By adjusting fibromodulin levels according to the specific disorder type and stage (excessive vs. deficient activity, early vs. prolonged phase), the treatment adapts to different clinical scenarios. This dynamic approach allows the same therapeutic mechanism to effectively address both short-duration and prolonged myofibroblast activity issues across various disorders
Data Source
AI summary
The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.